ReS3-T / ReMYND - LARVOL DELTA

reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program (GlobeNewswire) - "reMYND NV...announces the acceptance of ReS3-T, the Company’s lead epilepsy drug candidate, into the US NIH’s National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3)...The program offers screening of treatment compounds, with a focus on therapy-resistant epilepsies, disease prevention and modification and performs testing with high scientific rigor."

Licensing / partnership • CNS Disorders • Epilepsy